For many patients with advanced renal cell carcinoma, breast cancer, or neuroendocrine tumors, targeted therapy represents a critical source of hope—helping to extend survival and

On March 8, 2023, China’s National Medical Products Administration (NMPA) announced a significant glumetinib approval—the conditional market authorization of the Class 1 innovative drug Glumetinib Tablets

Nasopharyngeal carcinoma (NPC) was once regarded as a mysterious regional disease, as its incidence was exceptionally high in southern China, Southeast Asia, and other regions—particularly

In the field of autoimmune disease treatment, 2021 marked a significant milestone—the world’s first-in-class dual-target biologic drug Telitacicept (brand name: Tai Ai®), independently developed in

IgA nephropathy is the most common primary glomerular disease in China, accounting for approximately 40%–50% of all primary glomerulonephritis cases. For many years, the treatment

🤔 When well-defined red patches covered in silvery-white scales appear on the skin, it is often more than just a cosmetic concern—it reflects a “microscopic